Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2018-05-14 Director's Dealing
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an individual (Dr. Gerald Möller), their position ('Member of the administrative or supervisory body'), the nature of the transaction ('Acquisition'), the price, volume, and date of the transaction involving company shares. This content directly matches the definition for Director's Dealing.
2018-05-14 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under section 2. It details changes in the percentage of voting rights held by 'Templeton Funds Trust' in MorphoSys AG, referencing specific German securities laws (WpHG Sections 33, 34, 38). This content directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds. The code for this is MRQ.
2018-05-04 English
Q1 statement / Q1 financial report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'First Quarter Interim Statement' for the period January–March 2018. It contains detailed financial statements (Income Statement, Balance Sheet, Cash Flows) and comprehensive management discussion of business performance, pipeline updates, and financial results. It exceeds the length of a simple announcement and provides substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). Q1 2018
2018-05-03 German
MorphoSys AG Reports First Quarter 2018 Results (news with additional features)
Earnings Release Classification · 100% confidence The document is explicitly titled "MorphoSys AG Reports First Quarter 2018 Results" and contains detailed financial figures (Revenues, EBIT, Net Loss) for Q1 2018, along with operational updates and financial guidance for the remainder of 2018. This structure is characteristic of a comprehensive periodic financial report covering a period shorter than a full year. The presence of the IFRS financial review and the specific mention of Q1 2018 strongly points to an Interim/Quarterly Report, which corresponds to the 'IR' code. It is not an Earnings Release (ER) because it contains the full financial review and detailed segment breakdowns, not just highlights. It is also not an RPA because it contains the full results, not just an announcement that results are available. Q1 2018
2018-05-02 English
MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial With MOR106 in Atopic Dermatitis Patients (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a press release dated May 1, 2018, announcing the initiation of a Phase 2 clinical trial (IGUANA) for a drug candidate (MOR106) by two biotechnology companies, MorphoSys AG and Galapagos NV. It details the study design, objectives, and provides background information on the disease (Atopic Dermatitis) and the drug mechanism. This type of announcement, focusing on clinical trial progress and scientific/development updates, is characteristic of corporate news releases in the pharmaceutical/biotech sector. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a management discussion (MDA). Since it is a specific corporate announcement about clinical development, it fits best under the general 'Regulatory Filings' (RNS) category as a standard news release, or potentially 'LTR' if it were about legal proceedings, but here it is clearly about R&D progress. Given the options, RNS serves as the best fit for a general corporate news announcement that isn't explicitly defined elsewhere (like ER, CT, or specific financial reports). It is not a Report Publication Announcement (RPA) because it is the substantive content, not just an announcement that a report is available.
2018-05-01 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'MorphoSys AG: Release according to Article 41 of the WpHG' and specifically announces the 'Publication of total number of voting rights' following a 'Conditional capital increase'. This type of announcement, dealing with changes in the total number of voting rights due to capital structure changes, aligns most closely with categories related to capital structure or general regulatory updates. Since it is a specific announcement about voting rights and capital structure changes, it fits better under 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS). However, the core subject is the change in the total number of shares/voting rights resulting from a capital measure. The closest specific category that covers capital structure changes is 'Capital/Financing Update' (CAP). Given the specific nature of reporting total voting rights under German law (WpHG), it is a mandatory regulatory disclosure. Since there isn't a specific 'Voting Rights Change' code, and it relates to a capital measure, CAP is a strong candidate. Alternatively, because it is a formal regulatory disclosure transmitted via DGAP (a service for regulatory announcements), RNS is also plausible. Given the explicit mention of 'Type of capital measure' and the resulting 'New total number of voting rights', CAP is the most descriptive fit for the *content* of the change, even if RNS is the *delivery mechanism* for many such filings. I will classify it as CAP as it details a capital measure outcome.
2018-04-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.